耐受性
医学
内科学
药代动力学
药效学
不利影响
实体瘤疗效评价标准
肿瘤科
临床试验
临床研究阶段
药理学
胃肠病学
作者
Kenneth Sooi,Tuan Zea Tan,Jae‐Weon Kim,Jung Y. Lee,Byoung-Gie Kim,David Micklem,Akil Jackson,David J. Pinato,Charlie Gourley,Rebecca Kristeleit,Sarah P. Blagden,Line Bjørge,David S.P. Tan
标识
DOI:10.1038/s41416-025-03090-6
摘要
BACKGROUND: Tilvestamab is a highly selective humanised immunoglobulin G1 anti-AXL monoclonal antibody. This phase 1 study evaluated its optimal dose, safety, tolerability, immunogenicity and pharmacokinetics (PK) in relapsed platinum-resistant HGSOC patients. METHODS: Patients received tilvestamab in three dose levels (1 mg/kg, 3 mg/kg and 5 mg/kg) via IV infusion every 2 weeks. Primary objectives included safety, tolerability and PK. Exploratory objectives included overall response, progression-free survival (PFS) and quality-of-life measures. Pharmacodynamic included AXL expression, gene and protein changes by transcriptomic and proteomic analysis. RESULTS: Between 25 February 2021 and 4 February 2022, 16 patients were enroled across 8 sites in Singapore, Korea, United Kingdom, and Norway. Median treatment duration was 6.1 weeks. Grade 3 or higher treatment-emergent adverse events occurred in 62.5% patients, but none were tilvestamab-related. Common events included fatigue (38%), anorexia (38%) infections (31%), anaemia (25%) and dyspnoea (25%). No objective responses were observed, but 7 (44%) had stable disease at 6 weeks. PK showed dose-proportional exposure and steady-state by the second dose. Pharmacodynamic analyses revealed reduced fibrosis-related gene signatures and AXL protein expression. Epithelial-mesenchymal transition reversal was seen in 2 patients. CONCLUSION: Tilvestamab was well-tolerated and further studies to examine the efficacy of AXL inhibition in other indications are required. CLINICAL TRIAL REGISTRATION: This trial is registered at https://clinicaltrials.gov . REGISTRATION NUMBER: NCT04893551. EudraCT Number: 2020-001382-36.
科研通智能强力驱动
Strongly Powered by AbleSci AI